By accurately predicting the binding of MHC molecules with tumor-specific antigens, OnmiMHC can facilitate the design and optimization of personalized tumor vaccines, enhancing the specificity and effectiveness of treatment. The gene discussed is HLA-C; the disease is neoplasm.